Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
basal cell carcinoma |
| gptkbp:ATCCode |
gptkb:L01XX43
|
| gptkbp:CASNumber |
879085-55-9
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:hasMolecularFormula |
C19H14Cl2N2O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
GDC-0449
|
| gptkbp:indication |
locally advanced basal cell carcinoma
metastatic basal cell carcinoma |
| gptkbp:KEGGID |
D09722
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
Hedgehog pathway inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
24776410
DB08816 CHEMBL1229513 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue weight loss alopecia dysgeusia muscle spasms |
| gptkbp:synonym |
gptkb:Erivedge
Vismodegib |
| gptkbp:target |
gptkb:Smoothened_(SMO)_receptor
|
| gptkbp:UNII |
Y6B4H1P12A
|
| gptkbp:bfsParent |
gptkb:CHEMBL31808
|
| gptkbp:bfsLayer |
7
|